The Rise of BTK Inhibitors In CLL
Follow the Steps Below
Take A Pre Test
Watch A Video
Take A Post Test
Program Objective
The objective of this activity is to assess and enhance the knowledge of hematologists/oncologists on the use of BTK inhibitors in the management of CLL.
Take the Pre Test
Question 1/5
Which of the following lymphomas develops pre-germinal center?
aMutated CLL
bUnmutated CLL
cMultiple myeloma
dWaldenstrom macroglobulinemia
Take the Pre Test
Question 2/5
Which of the following B-cell activities are impaired by BTK inhibitors in the BTK signaling pathway?
aAdhesion
bMovement
cBCR signaling
dAll of the above
eNone of the above
Take the Pre Test
Question 3/5
What was the 7-year OS in patients with CLL treated with ibrutinib in the first line in the PCYC-1102 study?
a< 30%
b34%
c55%
d84%
Take the Pre Test
Question 4/5
Which medications should be avoided or used with caution in patients treated with acalabrutinib?
aProton pump inhibitors only
bCYP3A inhibitors only
cBoth proton pump inhibitors and CYP3A inhibitors
Take the Pre Test
Question 5/5
Zanubrutinib is currently indicated for the treatment of which of the following?
aCLL with del(17p)
bMCL after 1 or more prior therapies
cMZL in patients who have received at least 1 anti-CD20-based therapy
dR/R CLL with or without del(17p)
eMore than 1 of the above
Watch the Video
1.
Learning Module 1: Evolution of BTKi Therapy
Educational Speakers
Kerry Rogers, MD
The Ohio State University
Columbus, OH
Javier Pinilla, MD, PhD
H. Lee Moffitt Cancer Center
Tampa, FL
Post Test
Question 1/5
Which of the following lymphomas develops pre-germinal center?
aMutated CLL
bUnmutated CLL
cMultiple myeloma
dWaldenstrom macroglobulinemia
Post Test
Question 2/5
Which of the following B-cell activities are impaired by BTK inhibitors in the BTK signaling pathway?
aAdhesion
bMovement
cBCR signaling
dAll of the above
eNone of the above
Post Test
Question 3/5
What was the 7-year OS in patients with CLL treated with ibrutinib in the first line in the PCYC-1102 study?
a< 30%
b34%
c55%
d84%
Post Test
Question 4/5
Which medications should be avoided or used with caution in patients treated with acalabrutinib?
aProton pump inhibitors only
bCYP3A inhibitors only
cBoth proton pump inhibitors and CYP3A inhibitors
Post Test
Question 5/5
Zanubrutinib is currently indicated for the treatment of which of the following?
aCLL with del(17p)
bMCL after 1 or more prior therapies
cMZL in patients who have received at least 1 anti-CD20-based therapy
dR/R CLL with or without del(17p)
eMore than 1 of the above
Results
0%
0%
Question 1
Which of the following lymphomas develops pre-germinal center?
Correct Answer:
b: Unmutated CLL
Click here to see all answers
Correct Answer:
b: Unmutated CLL
Click here to see all answers
Question 2
Which of the following B-cell activities are impaired by BTK inhibitors in the BTK signaling pathway?
Correct Answer:
d: All of the above
Click here to see all answers
Correct Answer:
d: All of the above
Click here to see all answers
Question 3
What was the 7-year OS in patients with CLL treated with ibrutinib in the first line in the PCYC-1102 study?
Correct Answer:
d: 84%
Click here to see all answers
Correct Answer:
d: 84%
Click here to see all answers
Question 4
Which medications should be avoided or used with caution in patients treated with acalabrutinib?
Correct Answer:
c: Both proton pump inhibitors and CYP3A inhibitors
Click here to see all answers
Correct Answer:
c: Both proton pump inhibitors and CYP3A inhibitors
Click here to see all answers
Question 5
Zanubrutinib is currently indicated for the treatment of which of the following?
Correct Answer:
b: MCL after 1 or more prior therapies
Click here to see all answers
Correct Answer:
b: MCL after 1 or more prior therapies
Click here to see all answers